Cyclacel Pharmaceuticals Q1 EPS $(0.42) Beats $(0.68) Estimate

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.68) by 38.24 percent. This is a 16 percent increase over losses of $(0.50) per share

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.68) by 38.24 percent. This is a 16 percent increase over losses of $(0.50) per share from the same period last year.

Total
0
Shares
Related Posts
Read More

Earnings Outlook For Edap TMS

Edap TMS (NASDAQ:EDAP) is set to give its latest quarterly earnings report on Wednesday, 2022-11-16. Here's what investors need to know before the announcement. Analysts estimate that Edap TMS will report an earnings per share (EPS) of $-0.06.

EDAP